You are here:

perampanel (Fycompa)

Advice

Following a full submission:

perampanel (Fycompa®) is accepted for restricted use within NHS Scotland.

Indication under review: Adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

SMC restriction: use as a second-line adjunctive treatment in patients with refractory partial onset epilepsy. Treatment should be initiated only by physicians who have appropriate experience in the treatment of epilepsy.

In three placebo-controlled studies in patients with uncontrolled partial-onset seizures, perampanel was superior to placebo in terms of the proportion of patients experiencing a ≥50% reduction in partial seizure frequency per 28 days.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of perampanel. This SMC advice is contingent upon the continuing availability of the patient access scheme or a list price that is equivalent or lower.

Drug Details

Drug Name: perampanel (Fycompa)
SMC Drug ID: 819/12
Manufacturer: Eisai Ltd
Indication: As adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 10 December 2012

Back